Henlius Presents P-III Data of HLX04 (biosimilar, bevacizumab) at CSCO 2020

 Henlius Presents P-III Data of HLX04 (biosimilar, bevacizumab) at CSCO 2020

Henlius Presents P-III Data of HLX04 (biosimilar, bevacixumab) at CSCO 2020

Shots:

  • The P-III HLX04-mCRC03 study involve assessing of HLX04 (7.5mg/kg, q3w, when combined with XELOX or 5mg/kg, q2w when combined with mFOLFOX6) vs reference bevacizumab + CT (XELOX or mFOLFOX6) as a 1L treatment in 675 patients in a ratio (1:1) with mCRC
  • Results: PFSR36wk  (46.4% vs 50.7%); no difference in 2EPs including OS, PFS, ORR, TTR and DoR
  • HLX04 is a bevacizumab biosimilar, indicated for advanced, metastatic, or recurrent NSCLC and metastatic colorectal cancer. Additionally, NMPA has accepted NDA of HLX04

Click here ­to­ read full press release/ article | Ref: Henlius | Image: Henlius

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post